Apnimed, Inc. reported second quarter 2026 financial results and provided a corporate update on September 8, 2026. The company announced that the U.S. Food and Drug Administration accepted its New Drug Application for AD109 (proposed name Oxnimbi) to treat obstructive sleep apnea, assigning a PDUFA target action date of February 28, 2027. Apnimed completed an upsized initial public offering generating $220.8 million in gross proceeds and secured a senior secured credit facility for up to $150 million. Additionally, the company monetized its interest in Shionogi-Apnimed Sleep Science for $100 million in upfront proceeds. For the quarter ended June 30, 2026, Apnimed reported net income of $125.9 million, driven by gains on the reversal of a deposit liability and sale of an equity method investment, while cash and cash equivalents stood at approximately $172.8 million. The company operates in the pharmaceutical industry, focusing on the discovery and development of oral therapies for sleep-related breathing diseases.

Apnimed, Inc. filed its ninth amended and restated certificate of incorporation with the Delaware Secretary of State on August 3, 2026, in connection with the consummation of its initial public offering. The Restated Certificate authorizes 500,000,000 shares of common stock, eliminates references to previously existing preferred stock series, and authorizes 10,000,000 shares of undesignated preferred stock issuable at the Board's discretion. Concurrently, the second amended and restated bylaws became effective, establishing procedures for stockholder actions, advance notice requirements for proposals and director nominations, and conforming to the Restated Certificate provisions. Apnimed, Inc. operates in the biotechnology industry, focusing on the development of novel therapies.